Friedreich’s ataxia (FA) is a rare, autosomal recessive neurodegenerative disease whose natural history and clinical characterization have made significant progress in recent decades. Nevertheless, there is still a lack of sensitive, objective biomarkers that both reliably reflect disease progression and are practicable for clinical studies. The TRACK-FA study, the largest multicenter, multimodal neuroimaging study in FA to date, is now making a decisive contribution. It shows that structural and functional imaging markers not only detect disease-relevant changes, but also correlate with clinical scales. This opens up new avenues for more precise diagnostics, the development of therapies and the shortening of study durations.
Autoren
- Tanja Schliebe
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- From genome profiles to targeted therapies
Advances in breast cancer therapy in the age of molecular diagnostics
- Current overview of evidence, mechanisms and clinical implications
Apolipoprotein E and neuropsychiatric symptoms in neurocognitive disorders
- Rare pulmonary syndromes
Yellow nail and Swyer-James syndrome
- Parkinson's disease
Individual therapy management for an optimized outcome – an update
- Latent autoimmune diabetes in adults (LADA)
Looks like type 2, but is type 1
- Treatment of vitiligo
Focus on patient perspective and disease activity
- Vaccine-preventable respiratory diseases
RSV and pneumococci: recommendations for risk groups
- Circadian rhythm in asthma